Anticancer Drug Development, Getting Out from Bottleneck

Abstract

Drug development as a sensitive thermometer represents the scientific and technical power-engines for any countries. As a result, drug manufacture (highly competitive area) is pillar industry for small-range of developed countries and highest medical expenditures worldwide. Nonetheless, new anticancer drug discovery, development and manufacture were entering into bottleneck stage two decades ago. A declining successful rate of phase II and phase III anticancer drug evaluations is the grimmest situation for most leading anticancer drug developers worldwide. Profit is down every years. Owing to all these kinds of undesired factors, anticancer drug developments manufacturing and licensing have been highly risky over the past two decades. This article addresses key factors affecting anticancer drug developments and possible roadmaps for drug screening model and routine updating in all relevant countries are especially speculated.